Get a Free 60-Page Guide to Curing Prostate Cancer

References

  1. Cookson MS, Aus G, Burnett AL, Danby-Hagino ED, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, et al.: Variation In The Definition Of Biochemical Recurrence In Patients Treated For Localized Prostate Cancer: The American Urological Association Prostate Guidelines For Localized Prostate Cancer Update Panel Report And Recommendations For A Standard In The Reporting Of Surgical Outcomes. J Urol 177: 540-545, 2007.
  2. Critz FA and Levinson K.: 10-Year Disease-Free Survival Rates After Simultaneous Irradiation For Prostate Cancer With A Focus On Calculation Methodology. J Urol 172: 2232-2238, 2004.
  3. Han M, Partin AW, Piantadosi S, Epstein JI, and Walsh PC.: Era Specific Biochemical Recurrence-Free Survival Following Radical Prostatectomy For Clinically Localized Prostate Cancer. J Urol 166: 416-419, 2001.
  4. Krygiel JM, Smith DS, Homan SM, Sumner W, Nease RF, Brownson RC and Catalona WJ.: Intermediate Term Biochemical Progression Rates After Radical Prostatectomy And Radiotherapy In Patients With Screen Detected Prostate Cancer. J Urol 174: 126-130, 2005.
  5. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, and Kattan MW. Postoperative Nomogram Predicting The 10-Year Probability Of Prostate Cancer Recurrence After Radical Prostatectomy. J Clin. Onc. Vol. 23, (28): 7005-7012, 2005.
  6. Touijer K, Cronin AM, Vickers AJ, Secin FP, Bianco FJ, Guillonneau BD. Oncological Outcome After Laparoscopic Radical Prostatectomy: 10 Years Experience. J Urol 179, (4): 558, 2008.
  7. Badami KK, Kaul S, and Menon M.: Evolution Of Robotic Radical Prostatectomy. Assessment After 2766 Procedures. Cancer 110 (9): 1951–1958, 2007.
  8. Kuban D, Thames H, Levy L, Horwitx E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, and Zietman A.: Failure Definition — Dependent Differences In Outcome Following Radiation For Localized Prostate Cancer: Can One Size Fit All? Int J Rad Onc Biol Phys 61 (2): 409-414, 2005.
  9. Kuban DA, Levy LB, Potter L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, and Horwitz EM.: Comparison Of Biochemical Failure Definitions For Permanent Prostate Brachytherapy. Int J Rad Onc Biol Phys. 65 (5): 1487-1493, 2006.
  10. Ragde H, Elgamal AA, Snow PB, Brandt J, Bartolucci AA, Nadir BS, and Kirb LJ.: Ten-Year Disease Free Survival After Transperineal Sonography-Guided Iodine-125 Brachytherapy With Or Without 45-Gray External Beam Irradiation In The Treatment Of Patients With Clinically Localized, Low To High Gleason Grade Prostate Carcinoma. Cancer 83 (5): 989-1001, 1998.
  11. Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, and Katz AE.: Whole Gland Primary Prostate Cryoablation: Initial Results From The Bryo On-Line Data Registry. J Urol 180:554-558, 2008.
  12. Demanes DJ, Rodrigues RR, Schour L, Brandt D, And Altieri G.: High-Dose –Rate Intensity-Modulated Brachytherapy With External Beam Radiotherapy For Prostate Cancer: California Endocurietherapy’s 10-Year Results. Int J Rad Onc Biol Phys, 61 (5): 1306-1316, 2005.
  13. Slater JD, Rossi CJ, Yonemoto LT, Bush DA, Jabola BR, Levy RP, Grove RI, Preston W, and Slater JM.: Proton Therapy For Prostate Cancer: The Initial Loma Linda University Experience. Int J. Rad Onc Biol Phys. 59 (2): 348-352, 2004.
  14. Koch MO, Gardner T, Cheng L, Fedewa RJ, Seip R, and Sangvhi NT.: Phase I/II Trial Of High Intensity Focused Ultrasound For The Treatment Of Previously Untreated Localized Prostate Cancer. J Urol 178: 2366-2371, 2007.
  15. Bentzen SM, Wasserman TH. Editorial: Balancing A Knife’s Edge: Evidence-Based Medicine And The Marketing of Health Technology. Int J Rad Onc Biol Phys vol. 72 (1), 2008.
  16. Abd TT, Goodman M, Hall JA, Petros JA, Marshall FF, And Issa MM.: Prostate Cancer Diagnosis Is Independent Of The Number Of Cores Obtained At Biopsy. J Urol 179 (4) Supplement: 716, 2008.
  17. Linson PW, Lee AK, Doytchinova T, Chen MH, Weinstein MH, Richie JP, and D’Amico AV.: Percentage Of Core Lengths Involved With Prostate Cancer: Does It Add To The Percentage Of Positive Prostate Biopsies In Predicting Postoperative Prostate-Specific Antigen Outcome For Men With Intermediate-Risk Prostate Cancer? Urol 59 (5): 704-708, 2002.
  18. Association of Directors of Anatomic and Surgical Pathology.: Recommendations For The Reporting of Prostate Carcinoma. Am J Clin Pathol 129: 24-30, 2008.
  19. Epstein JI, Allsbrook WC, Amin MB, and Egevad LL, and the ISUP Grading Committee.: The 2005 International Society Of Urological Pathology (ISUP) Consensus Conference On Gleason Grading Of Prostatic Carcinoma. Am J Surg Pathol 29 (9): 1228-1242, 2005.
  20. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presit JC, Dorey F, and Terris MK.: Comparison Of Percentage Of Total Prostate Needle Biopsy Tissue With Cancer To Percentage Of Cores With Cancer For Predicting PSA Recurrence After Radical Prostatectomy: Results From The Search Database. Urol 61 (4): 742-747, 2003.
  21. Cheng L, Davidson DD, Lin H, and Kock MO.: Percentage Of Gleason Pattern 4 And 5 Predicts Survival After Radical Prostatectomy. Cancer 110 (9): 1967-1972, 2007.
  22. Bastacky SI, Walsh PC, and Epstein JI: Relationship Between Perineural Tumor Invasion On Needle Biopsy And Radical Prostatectomy Capsular Penetration In Clinical Stage B Adenocarcinoma Of The Prostate. Am J Surg. Path 17 (4): 336-341, 1993.
  23. Lee IH, Roberts R, Shah RB, Wojno KJ, Wei JT, and Sandler HM.: Perineural Invasion Is A Marker For Pathologically Advanced Disease In Localized Prostate Cancer. Int J Rad Onc Biol Phys. 68 (4): 1059-1064, 2007.
  24. Harnden P, Shelley MD, Clements H, Coles B, Tyndale-Biscoe, RS, Naylor B, and Mason MD: The Prognostic Significance Of Perineural Invasion In Prostatic Cancer Biopsies. Cancer 109 (1): 13-24, 2007.
  25. D’Amico, AV, Wu Y, Chen MH, Nash M, Renshaw AA, and Richie JP.: Perineural Invasion As A Predictor Of Biochemical Outcome Following Radical Prostatectomy For Select Men With Clinically Localized Prostate Cancer. J Urol 165: 126-129, 2000.
  26. Villers A, McNeal JE, Redwine EA, Freiha FS, and Stamey TA: The Role Of Perineural Space Invasion In The Local Spread Of Prostatic Adenocarcinoma. J Urol 142: 763-768, 1989.
  27. Hassan MO, Maksem J: The Prostatic Perineural Space and Its Relation To Tumor Spread. Am J Surg Path 4 (2): 143-148, 1980.
  28. Thomas CW, Bainbridge TC, Thomson TA, McGahan CE, And Morris WJ.: Clinical Impact Of Second Pathology Opinion: A Longitudinal Study Of Central Genitourinary Pathology Review Before Prostate Brachytherapy. Brachytherapy 6: 135-141, 2007.
  29. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, and Partin AW.: Updated Nomogram To Predict Pathologic Stage Of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, And Biopsy Gleason Score (Partin Tables) Based on Cases from 2000-2005. Urol 69 (6): 1095-1101, 2007.
  30. Kundu SD, Cronin AM, Bianco FJ, Scardino PT, Eastham JA, and Vickers AJ.: How Common Is Late Recurrence After Radical Prostatectomy? J Urol 179 (4) Supplement: p. 204: 2008.
  31. Klein EA, Bianco FJ, Serio AM, Eastham JA, Kattan MW, Pontes JE, Vickers AJ and Scardino PT.: Surgeon Experience Is Strongly Associated With Biochemical Recurrence After Radical Prostatectomy for All Preoperative Risk Categories. J Urol 179: 2212-2217, 2008.
  32. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, and Crawford ED.: Predominant Treatment Failure In Postprostatectomy Patients Is Local: Analysis Of Patterns Of Treatment Failure In SWOG 8794. J Clin Onc 16 (25): 2225-2229, 2007.
  33. Parsons JK and Bennett JL.: Outcomes Of Retropubic, Laparoscopic, And Robotic-Assisted Prostatectomy. Urol 72 (2): 412-416, 2008.
  34. Smith JA, Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, and Cookson MS.: A Comparison Of The Incidence And Location Of Positive Surgical Margins In Robotic Assisted Laparoscopic Radical Prostatectomy And Open Retropubic Radical Prostatectomy. J Urol 178: 2385-2390, 2007.
  35. Trock BJ, Gui CC, Tamas EF, and Epstein, JI.: Prognostic Significance Of Positive Surgical Margins In Radical Prostatectomies: An Analysis Based On Their Anatomic Locations. J Urol 179 (4) Supplement: 197, 2008.
  36. Masieri L, Serni S, Lanciotti M, Minervini A, Lapini A, and Carini M.: Prostatic Apex Involvement In The Specimen Of Radical Prostatectomy Is An Independent Prognostic Factor Of Tumor Progression. J Urol 179 (4) Supplement: 495, 2008.
  37. Desireddi NV, Roehl KA, Loeb S, Yu X, Griffin CR, Kundu SK, Han M, and Catalona WJ.: Improved Stage And Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy In The PSA Era. Urol 70 (5): 950-955, 2007.
  38. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley WJ, Albertsen PC, Harlan LC, and Potosky AL.: Urinary And Sexual Function After Radical Prostatectomy For Clinically Localized Prostate Cancer. The Prostate Cancer Outcomes Study. JAMA 283 (3): 354-360, 2000.
  39. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, and Stanford JL.: 5-Year Urinary And Sexual Outcomes After Radical Prostatectomy: Results From The Prostate Cancer Outcomes Study. J Urol 713: 1701-1705, 2005.
  40. Touijer K, Eastham JA, Secin FP, Otero JR, Serio A, Stasi J, Sanchez-Salas R, Vickers A, Reuter VE, Scardino PT, and Guillonneau B.: Comprehensive Prospective Comparative Analysis Of Outcomes Between Open And Laparoscopic Radical Prostatectomy Conducted In 2003 to 2005. J Urol 179: 1811-1817, 2008.
  41. Sandhu JS, Koppie TM, Cronin AM, Vora KC, Rabbani F, Touijer K, Guillonneau BD, Vickers AJ, Eastham JA, and Scardino PT.: Predictors Of Urinary Continence After Contemporary Radical Prostatectomy. J Urol 179 (4) Supplement: 610, 2008.
  42. Krambeck AE, DiMarco DS, Rangel LJ, Bergstralh EJ, Blute ML and Gettman MT.: Radical Prostatectomy For Prostatic Adenocarcinoma: Matched Comparison Of Retropubic And Robot Assisted Techniques. J Urol 179 (4) Supplement: 555, 2008.
  43. Karakiewica PI, Eastham JA, Graefen M, Cagiannos I, Stricker PD, Klein E, Cangiano T, Schroder FH, Scardino PT, and Kattan MW.: Prognostic Impact Of Positive Surgical Margins In Surgically Treated Prostate Cancer: Multi-Institutional Assessment of 5,831 Patients. Urol 66 (6): 1245-1250, 2005.
  44. Smith JA and Herrell SD: Robotic-Assisted Laparoscopic Prostatectomy: Do Minimally Invasive Approaches Offer Significant Advantages? J Clin Onc. 23 (32): 8170-8175, 2005.
  45. Schroech FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ, Robertson CN, Tewari AK, and Moul JW: Satisfaction And Regret After Open Retropubic Or Robot-Assisted Laparoscopic Radical Prostatectomy. Euro Urol Doi: 10.1016/j.euruo 2008.
  46. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, The BS, Klein EA, Kupelian PA, Scardino PT, et al.: Salvage Radiotherapy For Recurrent Prostate Cancer After Radical Prostatectomy. JAMA 291 (11): 1325-1332, 2004.
  47. Ward JF, Sebo TJ, Blute ML, and Zincke H.: Salvage Surgery For Radiorecurrent Prostate Cancer: Contemporary Outcomes. J Urol 173: 1156-1160, 2005.
  48. Walsh P. Editorial Comment – Defining Biochemical Failure Following Radiotherapy With Or Without Hormonal Therapy In Men With Clinically Localized Prostate Cancer: Recommendations Of The RTOG-ASTRO Phoenix Consensus Conference. J Urol 177: 551, 2007.
  49. Roach, M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, and Sanderl H.: Defining Biochemical Failure Following Radiotherapy With Or Without Hormonal Therapy In Men With Clinically Localized Prostate Cancer: Recommendations Of The RTOG-ASTRO Phoenix Consensus Conference. Int J Rad Onc Biol Phys, 65 (4): 965-974, 2006.
  50. Kaplan DJ, Crispen PL, Greenberg RE, Chen DYT, Viterbo R, Bouyyounouski MK, Horwitz EM and Uzzp, RG: Residual Prostate Cancer After Radiotherapy: A Study Of Radical Cystoprostatectomy Specimens. Urol 72 (3): 654-658, 2008.
  51. Nielson ME, Makarov DV, Humphreys E, Mangold L, Partin AW, and Walsh PC.: Is It Possible To Compare PSA Recurrence-Free Survival After Surgery And Radiotherapy Using Revised ASTRO Criterion – “Nadir+2”? Urol 72 (2): 389-395, 2008.
  52. Gretzer MB, Trock BJ, Han M, et al: A Critical Analysis Of The Interpretation Of Biochemical Failure In Surgically Treated Patients Using The American Society For Therapeutic Radiation And Oncology Criteria. J Urol 168: 1419-1422, 2002.
  53. Critz FA.: A Standard Definition Of Disease Freedom Is Needed For Prostate Cancer: Undetectable Prostate Specific Antigen Compared With The American Society Of Therapeutic Radiology And Oncology Consensus Definition. J Urol 167: 1310-1313, 2002.
  54. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, and Amols H.: Ultra-High Dose (86.4 GY) IMRT For Localized Prostate Cancer: Toxicity And Biochemical Outcomes. Int J Rad Onc Biol Phys. 71 (2): 330-337, 2008.
  55. Peeters STH, Heemsbergen WD, Koper PCM, Van Putten WLJ, Slot A, Dielwart MFH, Bonfrer JMG, Incrocci L, and Lebesque JV.: Dose-Response In Radiotherapy For Localized Prostate Cancer: Results Of The Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy. J Clin Onc 24 (13): 1990-1996, 2006.
  56. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, and Jones JS.: Salvage Prostate Cryoablation: Initial Results From The Cryo On-Line Data Registry. J Urol 180: 559-564, 2008.
  57. Murat FJ, Poissonnier L, Rouviere O, Pasticier G, Martin X, Chapelon JY, and Gelet A.: Salvage HIFU Following A Post External Beam Radiation Therapy Localized Recurrence: A Valid And Effective Treatment Option. J Urol 179 (4) Supplement: 400, 2008.
  58. Walsh PC, DeWeese TL, and Eisenberger MA.: Localized Prostate Cancer. N Engl J Med 357: 2696-2705, 2007.
  59. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, and Epstein JI.: Expectant Management of Prostate Cancer With Curative Intent: An Update Of The Johns Hopkins Experience. J Urol 178: 2359-2365, 2007.
  60. Dall’Era, MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez M, Master VA, And Carroll PR.: Active Surveillance For The Management Of Prostate Cancer In A Contemporary Cohort. Cancer 112 (12): 2664-2670, 2008.
  61. Liu SL, Spaic T, Van Uum, SH, Pautler SE, Nott L, and Razvi H.: High Incidence Of Previously Undiagnosed Diabetes Mellitus In Patients On Androgen Deprivation Therapy Compared To A Control Group. J Urol 179 (4) Supplement: 185, 2008.
  62. Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Encabo G, and Reventos J.: Prevalence Of Osteoporosis During Long-Term Androgen Deprivation Therapy In Patients With Prostate Cancer. Urol 69 (3): 500-504, 2007.
  63. Smith MR, Lee H, McGovern F, Fallon AM, Goode M, Zietman AL, and Finkelstein JS.: Metabolic Changes During Gonadotropin-Releasing Hormone Agonist Therapy For Prostate Cancer. Differences From The Classic Metabolic Syndrome. Cancer 112 (10):2188-2194, 2008.
  64. Tsai HK, D’Amico AV, Sadetsky N, Chen MH, And Carroll PR. Androgen Deprivation Therapy For Localized Prostate Cancer And The Risk Of Cardiovascular Mortality. J Nat Cancer Inst 99 (20): 1516-1524, 2007.
  65. Nelson CH, Lee JS, Gamboa MC, and Roth AJ. Cognitive Effects Of Hormone Therapy In Men With Prostate Cancer. Cancer 113 (5) 1097-1106.
  66. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, and Shipley WU.: Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction And Radiotherapy In Locally Advanced Carcinoma Of The Prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Onc 21 (21) 3972-3978, 2003.
  67. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, and Kantoff PW.: Androgen Suppression And Radiation Vs Radiation Alone For Prostate Cancer. JAMA 299 (3): 289-294, 2008.
  68. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, and Shipley WU.: Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial Of The Duration Of Elective Androgen Deprivation In Locally Advanced Prostate Cancer. J Clin Onc 26 (15): 2497-2504, 2008.
  69. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E, and Lief J.: Androgen Deprivation Therapy Does Not Impact Cause-Specific Or Overall Survival In High-Risk Prostate Cancer Managed With Brachytherapy And Supplemental External Beam. Int J Rad Onc Biol Phys 68 (1):34-40, 2007.
  70. Beyer DC, McKeough T, and Thomas T.: Impact Of Short Course Hormonal Therapy On Overall And Cancer Specific Survival After Permanent Prostate Brachytherapy. Int J Rad Onc Biol Phys 61 (5): 1299-1305, 2005.
  71. Klotz LH, Goldenberg SL, Jewett MAS, Fradet Y, Nam R, Barkin J, Chin J, Chatterjee S, and The Canadian Uro-Oncology Group. Long-Term Followup Of A Randomized Trial Of 0 Versus 3 Months Of Neoadjuvant Androgen Ablation Before Radical Prostatectomy. J Urol 170: 791-794, 2008.
  72. Critz FA: Bladder Cancer Associated With Brachytherapy For Prostate Cancer. J Urol 171:76, 2004. (Abstract).
  73. Blasko JC, Grimm PD, Sylvester JE, Cavanagh W. The Role Of External Beam Radiotherapy With I-125/Pd-103 Brachytherapy For Prostate Carcinoma. Radiotherapy and Onc 57: 273-278, 2000.
  74. Sarosdy MF. Urinary And Rectal Complications of Contemporary Prostate Brachytherapy (PB) For Prostate Cancer (PC). J Urol 169: 491, 2003.
  75. Patel J, Worthen R, Abadir R, Weaver DJ, Weinstein S, Ross G.: Late Results Of Combined Iodine-125 And External Beam Radiotherapy I Carcinoma of Prostate. Urology 36: 27-30, 1990.